Antihistamines with cationic amphiphilic drug (CAD) characteristics induce cancer-specific cell death in experimental studies. Epidemiologic evidence is, however, limited. In a Danish nationwide cohort of ovarian cancer patients diagnosed during 2000–2015 (n = 5075), we evaluated the association between filled antihistamine prescriptions and cancer mortality. We used Cox regression models to estimate hazard ratios (HRs) with 95% confidence intervals (CIs) for ovarian cancer mortality. In an in vitro cell viability assay, we evaluated cell death in three ovarian cancer cell lines after treatment with clinically relevant doses of eight antihistamines. In our cohort study, CAD antihistamine use (≥1 prescription; n = 133) was associated with a hazard ratio of 0.63 (95% CI = 0.40 to 0.99) compared to use of non-CAD antihistamines (n = 304), and we found a tendency toward a dose-response association. In our cell viability assay, we found consistent and dose-dependent cytotoxicity for all CAD but not non-CAD antihistamines. In this nationwide cohort study, use of antihistamines with CAD characteristics is associated with a prognostic benefit in ovarian cancer patients.

中文翻译：

---

抗组胺药和卵巢癌的生存：全国队列研究和体外细胞生存力测定。

在实验研究中，具有阳离子两亲药物（CAD）特征的抗组胺药可诱导特定于癌症的细胞死亡。但是，流行病学证据有限。在丹麦全国范围内于2000年至2015年期间诊断出的卵巢癌患者队列中（n = 5075），我们评估了抗组胺药处方与癌症死亡率之间的关系。我们使用Cox回归模型以95％置信区间（CIs）评估卵巢癌死亡率的危险比（HRs）。在体外细胞生存力测定中，我们用临床相关剂量的八种抗组胺药治疗后，评估了三种卵巢癌细胞系中的细胞死亡。在我们的队列研究中，与使用非CAD抗组胺药（n = 304）相比，使用CAD抗组胺药（≥1处方； n = 133）的危险比为0.63（95％CI = 0.40至0.99），并且我们发现了一种趋向于剂量-反应关联的趋势。在我们的细胞生存力测定中，我们发现所有CAD而非非CAD抗组胺药均具有一致且剂量依赖性的细胞毒性。在这项全国性队列研究中，使用具有CAD特征的抗组胺药与卵巢癌患者的预后获益相关。